These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38252673)

  • 21. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
    Coura JR; de Abreu LL; Willcox HP; Petana W
    Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mother-to-child transmission of congenital Chagas disease, Japan.
    Imai K; Maeda T; Sayama Y; Mikita K; Fujikura Y; Misawa K; Nagumo M; Iwata O; Ono T; Kurane I; Miyahira Y; Kawana A; Miura S
    Emerg Infect Dis; 2014 Jan; 20(1):146-8. PubMed ID: 24378113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of congenital Trypanosoma cruzi infection: A serologic test using Shed Acute Phase Antigen (SAPA) in mother-child binomial samples.
    Volta BJ; Russomando G; Bustos PL; Scollo K; De Rissio AM; Sánchez Z; Cardoni RL; Bua J
    Acta Trop; 2015 Jul; 147():31-7. PubMed ID: 25847262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
    Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
    Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase].
    Silveira CA; Castillo E; Castro C
    Rev Soc Bras Med Trop; 2000; 33(2):191-6. PubMed ID: 10881133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.
    Bianchi F; Cucunubá Z; Guhl F; González NL; Freilij H; Nicholls RS; Ramírez JD; Montilla M; Flórez AC; Rosas F; Saavedra V; Silva N
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003465. PubMed ID: 25723465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic effects of benznidazole in Swiss mice that are orally inoculated with Trypanosoma cruzi IV strains from the Western Brazilian Amazon.
    Teston APM; Fernandes NS; Abegg CP; de Abreu AP; Sarto MPM; Gomes ML; Toledo MJO
    Exp Parasitol; 2021 Sep; 228():108136. PubMed ID: 34280400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole.
    Chippaux JP; Clavijo AN; Santalla JA; Postigo JR; Schneider D; Brutus L
    Trop Med Int Health; 2010 Jan; 15(1):87-93. PubMed ID: 19968839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
    Filardi LS; Brener Z
    Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
    Castro JA; de Mecca MM; Bartel LC
    Hum Exp Toxicol; 2006 Aug; 25(8):471-9. PubMed ID: 16937919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 38. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
    Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
    PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trypanocidal therapy among children infected by Trypanosoma cruzi. Serological and electrocardiographic changes over a mean twenty-five-years follow-up period.
    Suasnábar S; Olivera LV; Arias E; Bizai ML; Bottasso O; Arias E; Fabbro D
    Acta Trop; 2021 Oct; 222():106050. PubMed ID: 34302770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Paediatric Chagas in a non-endemic area].
    Fumadó V; Juncosa T; Posada E; Fisa R; Gállego M; Gascón J
    Enferm Infecc Microbiol Clin; 2014 May; 32(5):293-6. PubMed ID: 24491481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.